Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.

ABSTRACT:

Background

Inflammatory and metabolic biomarkers have been associated with hepatocellular cancer (HCC) risk in phases I and II biomarker studies. We developed and internally validated a robust metabolic biomarker panel predictive of HCC in a longitudinal phase III study.

Methods

We used data and banked serum from a prospective cohort of 2266 adult patients with cirrhosis who were followed until the development of HCC (n=126). We custom designed a FirePlex immunoassay to measure baseline serum levels of 39 biomarkers and established a set of biomarkers with the highest discriminatory ability for HCC. We performed bootstrapping to evaluate the predictive performance using C-index and time-dependent area under the receiver operating characteristic curve (AUROC). We quantified t

SUBMITTER: El-Serag H 

PROVIDER: S-EPMC11327383 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature